Idarubicin
Myelodysplastic/Myeloproliferative Neoplasm
Explore 42 assets in Myelodysplastic/Myeloproliferative Neoplasm →Floatz Rating
BB66/100
Confidence
Indicative
Sponsor
Fred Hutchinson Cancer Center
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
55Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06034470CT.gov Combination Chemotherapy (FLAG-Ida) With Pivekimab Sunirine (PVEK) for the Treatment of Newly Diagnosed Adverse Risk Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms | — | Active Not Recruiting | — | — | — |
NCT00005823CT.gov Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Myelodysplastic/Myeloproliferative Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Idarubicin (this asset) | Fred Hutchinson Cancer Center | P3 | BB · 66 |
| Etoposide | M.D. Anderson Cancer Center | P3 | BBB |
| Melphalan | M.D. Anderson Cancer Center | P2/3 | BBB |
| Cytarabine | Fred Hutchinson Cancer Center | P3 | BBB |
| Cyclosporin A | Memorial Sloan Kettering Cancer Center | P3 | BBB |
| Busulfanum | Jacqueline Garcia, MD | P2/3 | BBB |
| Fludarabine | Fred Hutchinson Cancer Center | P3 | BBB |
| Anti-Human T-Lymphocyte Immunoglobulin, Rabbit | M.D. Anderson Cancer Center | P2/3 | BBB |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | BBB |
+42 more in the Myelodysplastic/Myeloproliferative Neoplasm cohort
Other indications for Idarubicin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P4 | A · 81 |
| Acute Myeloid Leukemia With 11q23 Abnormalities | — | P2 | BBB · 76 |
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Idarubicin in Myelodysplastic/Myeloproliferative Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/idarubicin-myelodysplasticmyeloproliferative-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →